A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-04965842 On Qtc Interval In Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-04965842 On Qtc Interval In Healthy Volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs PF 4965842 (Primary) ; Moxifloxacin
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top